Loading cancer entity…
Loading cancer entity…
Clinical trials
10,627 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,641)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04986865 | A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas(PROBE) | terminated | Phase 1 | 31 | Antengene Biologics LimitedINDUSTRY | 2 | Jun 9, 2025 | clinicaltrials |
| NCT05265975 | A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL(SWATCH) | terminated | Phase 1 / Phase 2 | 54 | Antengene CorporationINDUSTRY | 1 |
| Jun 9, 2025 |
| clinicaltrials |
| NCT04034446 | CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL) | terminated | Early Phase 1 | 2 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT01350258 | Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps | terminated | Phase 1 / Phase 2 | 8 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT04189952 | Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma | terminated | Phase 2 | 2 | University of MiamiOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT02953509 | Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 178 | Gilead SciencesINDUSTRY | 3 | May 29, 2025 | clinicaltrials |
| NCT05788289 | A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma | terminated | Phase 2 | 4 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT02811679 | A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma | terminated | Phase 2 | 13 | Massachusetts General HospitalOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT04892264 | Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma | terminated | Phase 1 | 5 | Mayo ClinicOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT00626444 | Pilot Trial of Intravenous Vitamin C in Refractory Non-Hodgkin Lymphoma (NHL) | terminated | Phase 2 | 2 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT03994705 | Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 20 | Cartesian TherapeuticsINDUSTRY | 1 | May 15, 2025 | clinicaltrials |
| NCT02966730 | Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy | terminated | Early Phase 1 | 2 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT02823327 | Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma | terminated | — | 25 | AIDS Malignancy ConsortiumNETWORK | 1 | May 11, 2025 | clinicaltrials |
| NCT05833737 | Corneal Findings in Patients Treated With Belantamab Mafodotin | terminated | — | 12 | Medical University of ViennaOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT01532635 | A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives | terminated | Phase 2 | 4 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT04217317 | CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma | terminated | Phase 2 | 6 | Wake Forest University Health SciencesOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT04892446 | Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 36 | Gilead SciencesINDUSTRY | 3 | May 2, 2025 | clinicaltrials |
| NCT01352312 | Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma | terminated | Phase 1 | 10 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT04464798 | A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas | terminated | Phase 1 | 62 | CelgeneINDUSTRY | 6 | Apr 29, 2025 | clinicaltrials |
| NCT00848328 | Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma | terminated | Phase 2 | 30 | University of California, DavisOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT06941688 | Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed/Refractory Peripheral T-cell Lymphoma | terminated | Phase 2 | 17 | Seoul National University HospitalOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT02875223 | A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas | terminated | Phase 1 | 75 | CelgeneINDUSTRY | 5 | Apr 20, 2025 | clinicaltrials |
| NCT04047797 | Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT03486067 | Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma | terminated | Phase 1 | 183 | CelgeneINDUSTRY | 6 | Apr 17, 2025 | clinicaltrials |
| NCT03492125 | A Study Of The Selective PKC-β Inhibitor MS- 553 | terminated | Phase 1 / Phase 2 | 60 | MingSight Pharmaceuticals, IncINDUSTRY | 1 | Apr 10, 2025 | clinicaltrials |
| NCT03615105 | Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors | terminated | Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT04896658 | Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 10 | University of Maryland, BaltimoreOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT03871829 | Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab | terminated | Phase 2 | 88 | Janssen Research & Development, LLCINDUSTRY | 13 | Mar 30, 2025 | clinicaltrials |
| NCT04251065 | Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH | terminated | Phase 2 | 8 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT04553692 | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers | terminated | Phase 1 | 272 | IGM Biosciences, Inc.INDUSTRY | 5 | Mar 28, 2025 | clinicaltrials |
| NCT05296525 | Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL | terminated | Phase 1 / Phase 2 | 13 | Gamida Cell ltdINDUSTRY | 1 | Mar 25, 2025 | clinicaltrials |
| NCT04975399 | Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma | terminated | Phase 1 | 26 | CelgeneINDUSTRY | 3 | Mar 24, 2025 | clinicaltrials |
| NCT05293912 | SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma. | terminated | Phase 1 | 2 | Hangzhou Sumgen Biotech Co., Ltd.INDUSTRY | 1 | Mar 18, 2025 | clinicaltrials |
| NCT04419389 | APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)(R/R) | terminated | Phase 1 / Phase 2 | 1 | Aprea TherapeuticsINDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT04982471 | Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study | terminated | — | 36 | CelgeneINDUSTRY | 1 | Mar 11, 2025 | clinicaltrials |
| NCT03893682 | A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas | terminated | Phase 1 | 36 | Aptose Biosciences Inc.INDUSTRY | 1 | Mar 7, 2025 | clinicaltrials |
| NCT01997840 | ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 103 | CelgeneINDUSTRY | 1 | Mar 4, 2025 | clinicaltrials |
| NCT03457142 | Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy | terminated | Phase 2 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT04750941 | Study of Copanlisib and Ketogenic Diet | terminated | Phase 2 | 1 | Columbia UniversityOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT02291965 | Blood Samples to Identify Biomarkers of Busulfan | terminated | — | 139 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06655818 | Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM | terminated | Phase 1 / Phase 2 | 4 | GlaxoSmithKlineINDUSTRY | 2 | Mar 3, 2025 | clinicaltrials |
| NCT04700176 | A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma | terminated | Phase 2 | 1 | Hackensack Meridian HealthOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT02761187 | An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants | terminated | — | 4,253 | TakedaINDUSTRY | 15 | Feb 24, 2025 | clinicaltrials |
| NCT04895917 | Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis(DarPAL) | terminated | Phase 2 | 27 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT03683277 | IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic(IFM2014-01) | terminated | Phase 2 | 26 | Intergroupe Francophone du MyelomeNETWORK | 1 | Feb 19, 2025 | clinicaltrials |
| NCT04718675 | A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC) | terminated | Phase 1 / Phase 2 | 135 | Kronos BioINDUSTRY | 3 | Feb 17, 2025 | clinicaltrials |
| NCT04150965 | Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT | terminated | Phase 1 / Phase 2 | 14 | Multiple Myeloma Research ConsortiumNETWORK | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05348889 | First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies | terminated | Phase 1 / Phase 2 | 7 | Chimagen Biosciences, LtdINDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Jun 9, 2025source: clinicaltrials